FR901464 increased an FKTN splicing-reporter signal in HEK293 cells. Separately, it inhibited proliferation of cancer cells and human fibroblasts, showing that strong cellular activity did not establish tumor selectivity. [1,2]
FKTN pseudo-exon reporter response
Cell-based study · HEK293 cells carrying a mutant FKTN exon 5–6/intron 5 HiBiT reporter with c.647+2084G>T; wild-type reporter and DMSO controls [1]
FR901464 increased reporter output and promoted pseudo-exon skipping. The dose response peaked at 3 nM among the reported doses; the luminescence readout is not a binding-potency measurement.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 3 and 10 nM (Figure 1H); 10 μM for RT-PCR confirmation in Figure 1G
- Exposure duration
- 24 h after compound addition
- Method
- HiBiT luminescence with RT-PCR confirmation
- Vehicle
- DMSO
- Reported limits
- Figure 1 caption states mean ± SD, n = 4; shared assay Methods states three biological replicates. This discrepancy remains unresolved; no replicate count or significance is assigned to the adopted fold value.
Methods and source locations
Compound reported in the paper: FR901464; Compound label in the paper: FR901464
Evidence applies to the named parent compound in the reported model; analytical stereochemical identity and current Adooq lot equivalence were not established.
Results 2.1–2.2; Figure 1A–H; Methods Compounds and HiBiT assay
Mutant reporter luminescence relative to DMSO: HiBiT assay; exact fold from Results, not estimated from bars — Results 2.2; Figure 1H
Pseudo-exon skipping and unwanted exon skipping in patient-derived myotubes
Cell-based study · Cultured FCMD patient-derived myotubes carrying FKTN c.647+2084G>T [1]
FR901464 promoted skipping of the aberrant pseudo-exon, but higher concentrations also altered other FKTN exons. Fainter transcript bands at 10 nM than at 3 nM limited interpretation as selective correction.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 3 and 10 nM
- Exposure duration
- 1 day compound exposure after 5 days of differentiation (diagrams in Figures 1I and 2A)
- Method
- RT-PCR across FKTN exons 5–6 and 5–10
- Vehicle
- DMSO
- Reported limits
- No FR901464 protein-rescue endpoint is shown in the adopted panels. Independent donor replication for these specific FR panels is not established by the three-patient description.
Methods and source locations
Compound reported in the paper: FR901464; Compound label in the paper: FR901464
Evidence applies to the named parent compound in the reported model; analytical stereochemical identity and current Adooq lot equivalence were not established.
Results 2.2–2.3; Figures 1I and 2A; Methods Compounds, Cell culture and RNA isolation/RT-PCR
FKTN pseudo-exon and other exon composition: DMSO-controlled RT-PCR; no exact band densitometry inferred — Results 2.2–2.3; Figures 1I and 2A
Cancer-cell and fibroblast proliferation inhibition
Cell-based study · Colorectal cancer panel, COLO829 melanoma, HCC38 breast cancer, CT26 murine colon tumor cells, and human fibroblasts [2]
FR901464 inhibited proliferation in cancer cells and human fibroblasts; the fibroblast response does not support tumor-selective cytotoxicity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1–500 ng/ml tested
- Exposure duration
- Figure 1A IC50 exposure duration is not unambiguously assigned in the shared Methods
- Method
- Cell counting kit; IC50 defined relative to untreated-cell proliferation
- Vehicle
- DMSO
- Reported limits
- Shared Methods lists 1, 3, 6, 12 and 96 h for time-dependency experiments, without explicitly assigning Figure 1A IC50 duration. Experiments independently repeated at least three times; exact n and numerical SD for each adopted IC50 are not stated in the read text.
Methods and source locations
Compound reported in the paper: FR901464; Compound label in the paper: FR
Evidence applies to the named parent compound in the reported model; analytical stereochemical identity and current Adooq lot equivalence were not established.
Results Sensitivity of cancer cell lines; Figure 1A; Methods Drugs and chemicals and Drug treatment in cell culture
50% reduction in cellular proliferation versus untreated cells: Cell counting kit; values explicitly reported in Results — Results Sensitivity of cancer cell lines; Figure 1A; Methods Drug treatment in cell culture